Ganguly Sandip, Biswas Bivas, Bhattacharjee Sayanika, Ghosh Joydeep, Mukhopadhyay Sumit, Midha Divya, Dabkara Deepak
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.
Department of Radiology, Tata Medical Center, Kolkata, West Bengal, India.
Lung India. 2020 Mar-Apr;37(2):134-139. doi: 10.4103/lungindia.lungindia_370_19.
Small cell lung cancer (SCLC) constitutes 14%-20% of all lung cancers. Clinical data on SCLC are scarce in literature. To report clinical features and treatment outcome of SCLC treated at our center.
This is a single institutional data review of SCLC patients treated between June 2011 and December 2018. Patients were staged as either localized or extensive disease after appropriate staging work-up. Patients with localized disease were treated with concurrent chemoradiation with platinum-based chemotherapy. Those with extensive disease were treated with platinum based palliative chemotherapy. Clinicopathological characteristics, treatment details, and outcome were recorded in this study. Patients who received at least one cycle of chemotherapy were included for survival analysis as intent-to-treat analysis.
A total of 181 were patients registered with a median age of 62 years (range: 35-86 years) and male: female ratio of 166:15. Eighty-seven percent (n = 157) of patients had smoking history and 15% (n = 28) of patients had symptom of superior vena cava obstruction at baseline. Twenty-seven (15%) patients had localized disease at presentation. One hundred and twenty (66%) patients took systemic chemotherapy. Chemotherapy regimen was carboplatin only in 9 (7%), etoposide-carboplatin in 54 (45%), and cisplatin-etoposide in 57 (48%). Patients received median cycle number of 6 (range: 1-6). Of the evaluable 87 (73%) patients, initial response was complete response in 4, partial response in 57, stable disease in 20, and progressive disease in 6. Twenty patients received second-line chemotherapy at time of disease progression. After a median follow-up of 8.8 months (range: 0.3-46.1), median progression-free survival (PFS) of the whole population was 9.3 months.
Small cell carcinoma in our series had a high incidence of advanced stage (85%) and 13% of patients were nonsmoker. Only 66% of patients received palliative chemotherapy and achieved high disease control rate (>75%) in the evaluable patients with median PFS of 9.3 months.
小细胞肺癌（SCLC）占所有肺癌的14%-20%。关于SCLC的临床数据在文献中较为匮乏。本研究旨在报告我院中心治疗的SCLC的临床特征及治疗结果。
这是一项对2011年6月至2018年12月期间治疗的SCLC患者的单机构数据回顾。经过适当的分期检查后，患者被分为局限性或广泛性疾病。局限性疾病患者接受铂类化疗同步放化疗。广泛性疾病患者接受铂类姑息化疗。本研究记录了患者的临床病理特征、治疗细节及结果。接受至少一个周期化疗的患者纳入生存分析作为意向性分析。
共登记181例患者，中位年龄62岁（范围：35-86岁），男女比例为166:15。87%（n = 157）的患者有吸烟史，15%（n = 28）的患者基线时有上腔静脉阻塞症状。27例（15%）患者初诊时为局限性疾病。120例（66%）患者接受了全身化疗。化疗方案仅用卡铂的有9例（7%），依托泊苷-卡铂的有54例（45%），顺铂-依托泊苷的有57例（48%）。患者接受化疗的中位周期数为6个周期（范围：1-6个周期）。在可评估的87例（73%）患者中，初始反应为完全缓解4例，部分缓解57例，病情稳定20例，病情进展6例。20例患者在疾病进展时接受了二线化疗。中位随访8.8个月（范围：0.3-46.1个月）后，总体人群的中位无进展生存期（PFS）为9.3个月。
我们系列研究中的小细胞癌晚期发生率高（85%），13%的患者不吸烟。仅66%的患者接受了姑息化疗，在可评估患者中疾病控制率高（>75%），中位PFS为9.3个月。
